Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AstraZeneca PLC - American Depositary Shares
(NQ:
AZN
)
68.81
+0.85 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AstraZeneca PLC - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
March 13, 2025
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.
Via
Benzinga
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
March 12, 2025
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.
Via
Investor's Business Daily
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
March 12, 2025
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Via
Benzinga
One Week Is Currently Like A Decade In These Markets
March 09, 2025
It’s what they call a “low dollar market” in that general conditions aren’t easy and there aren’t many slam dunk no-brainer setups.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) suited for quality investing?
March 08, 2025
A fundamental analysis of (NASDAQ:AZN): This article explores why quality investors may have a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)
Via
Chartmill
What's a Good Price for AstraZeneca Stock?
February 19, 2025
Via
The Motley Fool
How Is The Market Feeling About AstraZeneca?
February 17, 2025
Via
Benzinga
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
March 07, 2025
AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival.
Via
Benzinga
IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
March 07, 2025
From
AstraZeneca
Via
Business Wire
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
March 06, 2025
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.
Via
Benzinga
Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring
March 06, 2025
Nvidia's CEO threw cold water on quantum computing by scoffing at its near-term utility. Quantum execs are sharpening their arguments.
Via
Investor's Business Daily
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
March 06, 2025
Via
Benzinga
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
March 03, 2025
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Via
Benzinga
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
March 01, 2025
From
AstraZeneca
Via
Business Wire
IonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla'
February 28, 2025
IonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry.
Via
Benzinga
Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek
February 27, 2025
Snowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex.
Via
Benzinga
Topics
Artificial Intelligence
Earnings
Exposures
Artificial Intelligence
Financial
AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines
February 26, 2025
AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.
Via
Benzinga
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
February 26, 2025
From
AstraZeneca
Via
Business Wire
Ranked: 10 Largest Companies In The U.S., Europe, And China
February 25, 2025
The top nine American companies by market cap are all worth more than a trillion dollars.
Via
Talk Markets
Topics
Stocks / Equities
Synchronicity: Denying The Unexplainable
February 24, 2025
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?
Via
Talk Markets
Topics
Stocks / Equities
3 Magnificent Growth Stocks to Buy Right Now
February 22, 2025
Via
The Motley Fool
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
February 21, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
February 20, 2025
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.
Via
Benzinga
AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN
February 19, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Big Money Is Betting On Europe, Should You? 3 ETFs To Watch
February 19, 2025
European fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF)
Via
Benzinga
Topics
ETFs
George Soros Makes Fresh Bets On Alphabet, Small Caps: What About SPY Puts And Alibaba?
February 19, 2025
Soros Fund Management made bullish bets on Alphabet and small-cap stocks while reducing exposure to SPY and Chinese tech in Q4.
Via
Benzinga
Deadline Soon: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
February 19, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 18, 2025
Via
Benzinga
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
February 15, 2025
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.